Detail akcie Regeneron Pharm online

Business Summary: Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company. The Company invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The Company is accelerating drug development using its proprietary technologies, such as VelociSuite, which produces optimized fully human antibodies and new classes of bispecific antibodies. VelociSuite consists of VelocImmune, VelociGene, VelociMouse, VelociMab, Veloci-Bi, VelociT, VelociHum, and other related technologies. Its marketed products include EYLEA (aflibercept); Dupixent (dupilumab); Libtayo (cemiplimab); Ordspono (odronextamab); Kevzara (sarilumab); Itepekimab; Linvoseltamab, and others.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2025, Regeneron Pharmaceuticals Inc revenues increased 1% to $14.34B. Net income before extraordinary items increased 3% to $4.55B. Revenues reflect Sanofi segment increase of 30% to $5.88B, EYLEA HD segment increase of 36% to $1.64B. Net income benefited from Changes in the fair value of our equity increase from $117.7M to $946.1M (income), Selling, general decrease of 10% to $2.34B (expense).